A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder.
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Levomilnacipran (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 16 Nov 2016 Results of a post-hoc analysis published in the International Clinical Psychopharmacology
- 20 May 2015 Pooled analysis (recurrent and first episode MDD) results presented at the 168th Annual Meeting of the American Psychiatric Association.
- 20 May 2015 Pooled analysis (noradrenergic symptoms, anxiety and functional impairment in adults) results presented at the 168th Annual Meeting of the American Psychiatric Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History